Voyager Therapeutics (NASDAQ:VYGR – Get Free Report) and Gritstone bio (NASDAQ:GRTS – Get Free Report) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their dividends, earnings, institutional ownership, risk, valuation, profitability and analyst recommendations.
Earnings and Valuation
This table compares Voyager Therapeutics and Gritstone bio”s gross revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Voyager Therapeutics | $250.01 million | 1.23 | $132.33 million | $0.71 | 7.94 |
| Gritstone bio | $496,000.00 | 7.05 | -$138.49 million | ($1.24) | -0.03 |
Voyager Therapeutics has higher revenue and earnings than Gritstone bio. Gritstone bio is trading at a lower price-to-earnings ratio than Voyager Therapeutics, indicating that it is currently the more affordable of the two stocks.
Analyst Recommendations
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Voyager Therapeutics | 0 | 1 | 7 | 1 | 3.00 |
| Gritstone bio | 0 | 3 | 0 | 1 | 2.50 |
Voyager Therapeutics presently has a consensus price target of $17.00, indicating a potential upside of 201.42%. Gritstone bio has a consensus price target of $2.17, indicating a potential upside of 6,628.78%. Given Gritstone bio’s higher probable upside, analysts plainly believe Gritstone bio is more favorable than Voyager Therapeutics.
Profitability
This table compares Voyager Therapeutics and Gritstone bio’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Voyager Therapeutics | 15.80% | 8.33% | 6.15% |
| Gritstone bio | -910.50% | -328.51% | -82.53% |
Insider and Institutional Ownership
48.0% of Voyager Therapeutics shares are held by institutional investors. Comparatively, 48.5% of Gritstone bio shares are held by institutional investors. 4.5% of Voyager Therapeutics shares are held by insiders. Comparatively, 4.6% of Gritstone bio shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.
Risk and Volatility
Voyager Therapeutics has a beta of 0.89, meaning that its share price is 11% less volatile than the S&P 500. Comparatively, Gritstone bio has a beta of 0.49, meaning that its share price is 51% less volatile than the S&P 500.
Summary
Voyager Therapeutics beats Gritstone bio on 10 of the 14 factors compared between the two stocks.
About Voyager Therapeutics
Voyager Therapeutics, Inc., a biotechnology company, focuses on the treatment of gene therapy and neurology diseases. The company's lead clinical candidate is VY-TAU01, an anti-tau antibody program for the treatment of alzheimer's disease. Its product pipeline includes superoxide dismutase 1 silencing gene therapy, which is in preclinical trial for the treatment of amyotrophic lateral sclerosis; tau silencing gene therapy, which is in preclinical trial for the treatment of alzheimer's disease; and vectorized anti-amyloid antibody, a gene therapy targeting anti-amyloid for the treatment of alzheimer's disease and is in preclinical trial. In addition, the company develops VY-FXN01, which is in preclinical trial to treat friedreich's ataxia; and GBA1 gene replacement to treat parkinson's disease and is in preclinical trial. Further, it provides research program for the treatment of Huntington's disease. The company has collaboration and license agreements with Alexion; AstraZeneca Rare Disease; Novartis Pharma AG; Neurocrine Biosciences, Inc; and Sangamo Therapeutics, Inc. Voyager Therapeutics, Inc. was incorporated in 2013 and is headquartered in Lexington, Massachusetts.
About Gritstone bio
Gritstone bio, Inc., a clinical-stage biotechnology company, engages in developing vaccine-based immunotherapy candidates against cancer and infectious diseases. Its primary product candidate is GRANITE, an individualized immunotherapy candidate, which is in Phase 2/3 clinical trials for the treatment of microsatellite stable colorectal cancers; and has completed Phase 1/2 clinical trials for treating solid tumors. The company is also developing SLATE, an off-the-shelf immunotherapy candidate, which is in Phase 2 clinical trials for the treatment of metastatic solid tumors. In addition, it develops CORAL, a COVID-19 vaccine program; and a therapeutic vaccine candidate that is in Phase 1 clinical trials designed to treat and cure human immunodeficiency virus (HIV) infection. Gritstone bio, Inc. has a strategic collaboration with bluebird bio, Inc.; collaboration agreement with Gilead Sciences, Inc.; and license agreement with Genevant Sciences GmbH. The company was formerly known as Gritstone Oncology, Inc. and changed its name to Gritstone bio, Inc. in May 2021. Gritstone bio, Inc. was incorporated in 2015 and is headquartered in Emeryville, California.
Receive News & Ratings for Voyager Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Voyager Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
